Role of antiestrogens and aromatase inhibitors in breast cancer treatment

David Jason Bentrem, V. Craig Jordan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


This review explores the recent experience with, and the basis for, the use of selective estrogen receptor modulators to treat and prevent breast cancer. As new agents are unveiled, they will continue to be tested against tamoxifen. A number of new selective estrogen receptor modulators are in clinical development in an attempt to decrease the unwanted effects of tamoxifen. Raloxifene holds the promise of treating osteoporosis with the beneficial side effect of breast cancer prevention. Additionally, two different classes of hormonal agents, the aromatase inhibitors and estrogen receptor down-regulators, which have no estrogen-like properties at any site, appear to be promising new treatments for advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)5-12
Number of pages8
JournalCurrent Opinion in Obstetrics and Gynecology
Issue number1
StatePublished - Mar 9 2002

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Role of antiestrogens and aromatase inhibitors in breast cancer treatment'. Together they form a unique fingerprint.

Cite this